In a report published Wednesday, Jefferies analyst David Steinberg downgraded the rating on Salix Pharmaceuticals, Ltd. SLXP from Buy to Hold, but raised the price target from $149.00 to $173.00.
In the report, Jefferies noted, "After a litany of suitors cast their bids, SLXP has agreed to be acquired by VRX in an all-cash transaction for $173. Post VRX's initial proposal of $158, we had thought there was a possibility another bid might emerge and indeed ENDP gave it a try. However, given VRX's improved terms and the fact that ENDP rescinded its final offer, we view the likelihood of a successful tender close on or near April 1 as very high. We thus downgrade SLXP from Buy to Hold."
Salix Pharmaceuticals closed on Tuesday at $172.48.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in